The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10617733 B1

Expired

Date of Patent:

Apr. 14, 2020

Filed:

Mar. 22, 2017

Orally consumable cannabinoid composition including lecithin

Applicant:

Rise Life Sciences Corp., Toronto, CA;

Inventor:

Brooks John Kelly, Denver, CO (US);

Assignee:

Rise Life Sciences Corp., Toronto, CA;

Attorney:

Kevin Fortin

Primary Examiner:

Kevin E Weddington

Int. Cl.

CPC ...

A61K 36/898 (2006.01); A61K 31/352 (2006.01); A61K 9/00 (2006.01); A61K 47/26 (2006.01); A61K 9/14 (2006.01); A61K 31/05 (2006.01); A61K 31/194 (2006.01); A61K 31/341 (2006.01); A61K 31/7004 (2006.01); A61K 36/06 (2006.01); A61K 36/074 (2006.01); A61K 36/185 (2006.01); A61K 36/752 (2006.01); A61K 36/81 (2006.01); A61K 31/375 (2006.01); A61K 31/75 (2006.01); A61K 36/068 (2006.01);

U.S. Cl.

CPC ...

A61K 36/898 (2013.01); A61K 9/0043 (2013.01); A61K 9/145 (2013.01); A61K 31/05 (2013.01); A61K 31/194 (2013.01); A61K 31/341 (2013.01); A61K 31/352 (2013.01); A61K 31/7004 (2013.01); A61K 36/06 (2013.01); A61K 36/074 (2013.01); A61K 36/185 (2013.01); A61K 36/752 (2013.01); A61K 36/81 (2013.01); A61K 47/26 (2013.01); A61K 31/375 (2013.01); A61K 31/75 (2013.01); A61K 36/068 (2013.01);

Abstract

The present invention relates to a pharmaceutical composition comprising non-decarboxylated Δ9 Tetrahydrocannabinol (THC), Cannabidiol (CBD), and at least one small molecule selected from Citric Acid, Ascorbic Acid, Citrus Essential Oil(s), Lecithin, one or more sugar(s), Resveratrol, and combinations thereof, wherein the composition exhibits enhanced therapeutic potency of THC and/or CBD. The present invention is further directed to methods of treating one or more disease(s) or disorder(s) modulated by the activation of the Cannabinoid CB1 and/or CB2 receptors, by administering a therapeutically effective amount of the composition of the present invention to a subject in need thereof.

Find Patent Forward Citations